Home About Us

About Us

AIMS & SCOPES

ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.

Editorial Office | 4960 South Gilbert Rd, Suite 1-286, Chandler, AZ 85249 (USA)

PUBLISHING TEAM

Peter Hofland
Peter Hofland, Ph.D is the Executive Editor of ADC Review, Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved drug. He is also a contributor to Onco'Zine and The Onco'Zine Brief. For more information about Hofland, check his ORCID profile here.
Shaun Mehr
Shaun Mehr is the Associate Publisher of ADC Review, Journal of Antibody-drug Conjugates and Onco'Zine, The International Journal of Oncology. He has over 20 years experience in custom publishing, advertising sales and media consulting for Fortune 100 companies including: Dell Technologies, Oracle and HP. He also has extensive association publishing experience, including representing the world's largest association of engineers, the IEEE.
Eric Rosenthal
Eric T. Rosenthal is an independent medical journalist specializing in providing insight, perspective, and transparency into various issues, trends, and controversies in oncology, and other areas concerning the politics of health care. He is Editor-at-Large at Onco'Zine and ADC Review | Journal of Antibody-drug Conjugates. ORCID Profile

PUBLISHER

Sunvalley Communication

Sunvalley Communication is a full-service, high science marketing, medical education and marketing communications agency, specializing in brand building, creative, editorial and communication strategies and publication planning for medical, pharmaceutical and life science companies.

FOUNDING SPONSOR

Lonza Pharma & Biotech

SITE SPONSOR

CONTENT PARTNERS

PRX

DIRECTORY PARTNERS

DISCLAIMER

ADC Review, Journal of Antibody-drug Conjugates is a peer reviewed journal with news, information and education sections. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a specific medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.